Pan-Asia Catalysts/Events, Quiddity Advisors

David Blennerhassett

Pan-Asia Catalysts/Events

Quiddity Advisors

Event-Driven

GoFintech Quantum Innovation / Event-Driven

<ul>
<li>
<a href="https://www.smartkarma.com/entities/sanergy-group-ltd" target="_blank" data-smartkarma-citation="entities:40079:1" rel="noopener">Sanergy (2459 HK)</a>, a graphite electrode manufacturer, was added to the MSCI Small-Cap Index on 30th August; and was due to enter the Hang Seng Composite Index on 9th September.</li>
<li>However, the SFC <a href="https://www.hkexnews.hk/listedco/listconews/sehk/2024/0902/2024090202067.pdf" target="_blank" rel="noopener">announced</a> a concentration warning on the 2nd September. Shares promptly cratered ~98% yesterday (the 3rd September). Expect the HSCI inclusion to now be yanked.</li>
<li>This Sanergy debacle should refocus investors on other heavily concentrated stocks, such as <a href="https://www.smartkarma.com/entities/jinhai-medical-technology-limited" target="_blank" data-smartkarma-citation="entities:40641:1" rel="noopener">Jinhai Medical (2225 HK)</a>, in which <a href="https://www.smartkarma.com/entities/gofintech-innovation-ltd" target="_blank" data-smartkarma-citation="entities:4384:1" rel="noopener">GoFintech (290 HK)</a> (another heavily concentrated stock) has inexplicably been buying. </li>
</ul>



Sanergy (2459 HK), a graphite electrode manufacturer, was added to the MSCI Small-Cap Index on 30th August; and was due to enter the Hang Seng Composite Index on 9th September.
However, the SFC announced a concentration warning on the 2nd September. Shares promptly cratered ~98% yesterday (the 3rd September). Expect the HSCI inclusion to now be yanked.
This Sanergy debacle should refocus investors on other heavily concentrated stocks, such as Jinhai Medical (2225 HK), in which GoFintech (290 HK) (another heavily concentrated stock) has inexplicably been buying. 


GoFinTech (290 HK)/Jinhai Medical (2225 HK): Double Bubble Trouble

Asia Pac ECM and Index Rebal, DZT Research

Ke Yan, CFA, FRM

Asia Pac ECM and Index Rebal

Asia Pac IPO & Placement Research, China Biotech

DZT Research

DZT Research is an independent Asia Pacific equity specialist. Our quantitative research covers index rebalancing flows, alongside exchange data analytics accross Asia Pacific. On the equity capital markets side, we focus on Asia Pacific ECM, especially biotech and TMT. Our lead analyst is frequently cited by international media.

Index Rebalance

<ul>
<li>We analyzed the performance of Hong Kong Connect implementation in March 2026.</li>
<li>ADD stocks reversed their bridge window drawdown at implementation. The bounce faded by week 3 to 4.</li>
<li>DELETE stocks fell through first week, exceeding Sep 2025. Within the DELETE basket, the names where connect investors sold the most also fell the most.</li>
</ul>


We analyzed the performance of Hong Kong Connect implementation in March 2026.
ADD stocks reversed their bridge window drawdown at implementation. The bounce faded by week 3 to 4.
DELETE stocks fell through first week, exceeding Sep 2025. Within the DELETE basket, the names where connect investors sold the most also fell the most.


HSCI / HK Connect (March 2026) Post-Event Review: What Worked, What Didn't

<ul>
<li>Hang Seng Index Company announced HSCI review results after market close on Feb 13. In our previous note, we reviewed the Sep 2025 HK Connect cycle.</li>
<li>In this note, we provide an update on the forecasted upcoming implementation action by the mainland exchanges based on implementation rules and highlight stock performance thus far.</li>
<li>Our analysis suggests that selectivity will be critical in this cycle, with differentiation driven by pre-positioning, narrative alignment, and ownership structure rather than mechanical inclusion alone.</li>
</ul>


Hang Seng Index Company announced HSCI review results after market close on Feb 13. In our previous note, we reviewed the Sep 2025 HK Connect cycle.
In this note, we provide an update on the forecasted upcoming implementation action by the mainland exchanges based on implementation rules and highlight stock performance thus far.
Our analysis suggests that selectivity will be critical in this cycle, with differentiation driven by pre-positioning, narrative alignment, and ownership structure rather than mechanical inclusion alone.


HK Connect March 2026: Implementation Forecast and Positioning Framework

<ul>
<li>We identify stocks likely to be added to the Hang Seng Composite Index in the upcoming review and, in turn, become eligible for Hong Kong Stock Connect.</li>
<li>Using market cap, free float and liquidity screens, we compile a preliminary list of potential inclusion candidates ahead of the review cut-off.</li>
<li>A follow-up note will focus on which inclusion candidates are most likely to translate eligibility into actionable trading opportunities.</li>
</ul>


We identify stocks likely to be added to the Hang Seng Composite Index in the upcoming review and, in turn, become eligible for Hong Kong Stock Connect.
Using market cap, free float and liquidity screens, we compile a preliminary list of potential inclusion candidates ahead of the review cut-off.
A follow-up note will focus on which inclusion candidates are most likely to translate eligibility into actionable trading opportunities.


HSCI / Hong Kong Connect Inclusion (March 2026): A Preliminary Assessment

Research and consultancy, Tabbush Report

Daniel Tabbush

Research and consultancy

Tabbush Report

We provide research and consultancy on Asian banks. Our focus is on what we call “Asian bank research, without the noise.” We are interested in the most critical swing-factors for banks, the NPL and credit cycle, and where we believe there is a gap between perception and reality. We often focus on the less studied components of bank financial statements.  Our research is highly thematic, sometimes examining unlisted banks and companies as a window on mainstream banks. 

Being independent allows us to look at smaller banks, often overlooked by others. Analysis of BIS bank guidelines in the context of Asia, is also a focal point, while we also analyze global banks operating in the region. We use what we believe is the most comprehensive, reliable financials database, SNL Financial. S&P Capital IQ augments our database, with corporate data and CEIC, with economics. 

Asian bank research, without the noise.

Thematic (Sector/Industry)

Where so many of us are focused on the impact of China slowdown on its banks, it is worth highlighting the risks to Hong Kong’s banks. But what we are focused on here is their domestic lending, not the stuff booked locally but for use in China. For most, the perception is that Hong Kong banks have little risk due to a strong emphasis on mortgage lending, but we are not convinced this is holding up, and we believe it will worsen.  Of course, the new marginally higher interest costs in Hong Kong…

Where so many of us are focused on the impact of China slowdown on its banks, it is worth highlighting the risks to Hong Kong’s banks. But what we are focused on here is their domestic lending, not the stuff booked locally but for use in China. For most, the perception is that Hong Kong banks have little risk due to a strong emphasis on mortgage lending, but we are not convinced this is holding up, and we believe it will worsen.  Of course, the new marginally higher interest costs in Hong Kong…

Domestic NPLs in Hong Kong Can Surprise – Not Just Those in Neighboring China

Hong Kong

GoFintech Quantum Innovation is an investment holding company providing a range of financial services including securities brokerage, margin financing, corporate finance, money lending, and asset management. It also engages in equity investment, supply chain operations, and investments in artworks. The company was founded in 2001 and is headquartered in Central, Hong Kong.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

GoFintech Quantum Innovation (290 HK)

GoFinTech (290 HK)/Jinhai Medical (2225 HK): Double Bubble Trouble

I would not touch GoFintech Innovation (290 HK) or Jinhai Medical (2225 HK) with a ten foot pole. I can see both companies making the news for all...

David Blennerhassett

HSCI / HK Connect (March 2026) Post-Event Review: What Worked, What Didn't

HK Connect Mar 2026 implementation cycle is completing. ADD reversed the WAI drawdown at implementation. DELETE continuation worked post...

Ke Yan, CFA, FRM

HK Connect March 2026: Implementation Forecast and Positioning Framework

March Connect implementation is nearing: we forecast expected ADD/DELETE actions and assess how positioning, crowding, and southbound flows may...

Ke Yan, CFA, FRM

HSCI / Hong Kong Connect Inclusion (March 2026): A Preliminary Assessment

We assess stocks potentially eligible for inclusion in the upcoming HSCI review and outline the resulting Hong Kong Stock Connect eligibility...

Ke Yan, CFA, FRM

Domestic NPLs in Hong Kong Can Surprise – Not Just Those in Neighboring China

Where so many of us are focused on the impact of China slowdown on its banks, it is worth highlighting the risks to Hong Kong’s banks. But what we...

Daniel Tabbush

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)